Jiantao Ma1, Shih-Jen Hwang1, Gearoid M McMahon1,2, Gary C Curhan2, Robert R Mclean3,4, Joanne M Murabito1,5, Caroline S Fox1. 1. National Heart, Lung, and Blood Institute's Framingham Heart Study and Population Sciences Branch, Framingham, Massachusetts, USA. 2. Renal Division, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA. 3. Hebrew SeniorLife, Institute for Aging Research, Boston, Massachusetts, USA. 4. Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA. 5. Section of General Internal Medicine, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA.
Abstract
OBJECTIVE: Midlife and contemporaneous cardiometabolic risk factors associated with sarcopenic obesity were examined. METHODS: Utilizing BMI and sex-specific 24-h urinary creatinine excretion, 1,019 participants from the Framingham cohorts were categorized as non-sarcopenia non-obese (NSNO), non-obese sarcopenia, non-sarcopenic obesity, and sarcopenic obesity. Cardiometabolic risk factors were quantified by standard laboratory assessment cross-sectionally and 10, 20, and 30 years before sarcopenic obesity assessment. RESULTS: NSNO, sarcopenia, obesity, and sarcopenic obesity accounted for 30.0%, 39.6%, 20.0%, and 10.4% of study participants, respectively. Cross-sectionally, participants with sarcopenic obesity had a higher proportion of hypertension, metabolic syndrome, and type 2 diabetes than those with NSNO or sarcopenia (all P < 0.03). Similar patterns were observed retrospectively at 10, 20, and 30 years. Compared with NSNO or sarcopenia, sarcopenic obesity was associated with a higher prevalence of type 2 diabetes at 10 years and hypertension and metabolic syndrome at all three time points before baseline (all P < 0.03). Individuals with sarcopenic obesity had more type 2 diabetes than those with obesity alone at baseline and 10 years prior (all P < 0.001). CONCLUSIONS: Older adults with sarcopenic obesity had more adverse midlife cardiometabolic risks, particularly diabetes 10 years earlier, which suggests the importance of early identification of risk factors associated with sarcopenic obesity.
OBJECTIVE: Midlife and contemporaneous cardiometabolic risk factors associated with sarcopenic obesity were examined. METHODS: Utilizing BMI and sex-specific 24-h urinary creatinine excretion, 1,019 participants from the Framingham cohorts were categorized as non-sarcopenia non-obese (NSNO), non-obese sarcopenia, non-sarcopenic obesity, and sarcopenic obesity. Cardiometabolic risk factors were quantified by standard laboratory assessment cross-sectionally and 10, 20, and 30 years before sarcopenic obesity assessment. RESULTS: NSNO, sarcopenia, obesity, and sarcopenic obesity accounted for 30.0%, 39.6%, 20.0%, and 10.4% of study participants, respectively. Cross-sectionally, participants with sarcopenic obesity had a higher proportion of hypertension, metabolic syndrome, and type 2 diabetes than those with NSNO or sarcopenia (all P < 0.03). Similar patterns were observed retrospectively at 10, 20, and 30 years. Compared with NSNO or sarcopenia, sarcopenic obesity was associated with a higher prevalence of type 2 diabetes at 10 years and hypertension and metabolic syndrome at all three time points before baseline (all P < 0.03). Individuals with sarcopenic obesity had more type 2 diabetes than those with obesity alone at baseline and 10 years prior (all P < 0.001). CONCLUSIONS: Older adults with sarcopenic obesity had more adverse midlife cardiometabolic risks, particularly diabetes 10 years earlier, which suggests the importance of early identification of risk factors associated with sarcopenic obesity.
Authors: Saro H Armenian; Wassim Chemaitilly; Marcus Chen; Eric J Chow; Christine N Duncan; Lee W Jones; Michael A Pulsipher; Alan T Remaley; Alicia Rovo; Nina Salooja; Minoo Battiwalla Journal: Biol Blood Marrow Transplant Date: 2016-08-30 Impact factor: 5.742
Authors: Ravi V Shah; Ashish S Yeri; Venkatesh L Murthy; Joe M Massaro; Ralph D'Agostino; Jane E Freedman; Michelle T Long; Caroline S Fox; Saumya Das; Emelia J Benjamin; Ramachandran S Vasan; Christopher J O'Donnell; Udo Hoffmann Journal: JAMA Cardiol Date: 2017-11-01 Impact factor: 14.676
Authors: Kathryn N Porter Starr; Margery A Connelly; Melissa C Orenduff; Shelley R McDonald; Richard Sloane; Kim M Huffman; William E Kraus; Connie W Bales Journal: J Clin Lipidol Date: 2019-10-02 Impact factor: 5.365
Authors: Cosmin Sebastian Voican; Amandine Lebrun; Sophie Maitre; Panagiotis Lainas; Karima Lamouri; Micheline Njike-Nakseu; Martin Gaillard; Hadrien Tranchart; Axel Balian; Ibrahim Dagher; Gabriel Perlemuter; Sylvie Naveau Journal: PLoS One Date: 2018-05-14 Impact factor: 3.240
Authors: Melyn Galbreath; Bill Campbell; Paul LaBounty; Jennifer Bunn; Jacqueline Dove; Travis Harvey; Geoffrey Hudson; Jean L Gutierrez; Kyle Levers; Elfego Galvan; Andrew Jagim; Lori Greenwood; Matthew B Cooke; Mike Greenwood; Chris Rasmussen; Richard B Kreider Journal: Nutrients Date: 2018-08-11 Impact factor: 5.717